PBSV Earnings Date & History
Pharma-Bio Serv Inc (OTC MARKETS) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Sep 13, 2026 at 1:27 AM ET
Pharma-Bio Serv Inc
Life Sciences Tools & Services
- Next earnings date
- Monday, September 14, 2026
- Reporting session
- Time TBD
- EPS estimate
- $0.03
- Revenue estimate
- $2.8M
PBSV earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Monday, June 15, 2026 | Q2 2026 | $0.03 | $0.01 | -67.3% | $2.7M |
| Tuesday, March 17, 2026 | Q1 2026 | $0.02 | $0.00 | -95.1% | $2.3M |
| Tuesday, March 17, 2026 | - | $0.02 | $0.00 | -95.1% | $2.3M |
| Monday, September 15, 2025 | Q3 2025 | $0.03 | $-0.01 | -129.4% | $2.0M |
What the market is watching in PBSV's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, daily catalyst context and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next PBSV earnings date?
- Pharma-Bio Serv Inc is scheduled to report on Monday, September 14, 2026 (Time TBD). Dates can change until the company confirms them.
- Does PBSV report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for PBSV?
- Consensus EPS for the upcoming quarter is $0.03, on revenue of $2.8M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
PBSV earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone, commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.